Accounting For the Majority of Nosocomial Infections, MRSA Is the Most Popular Target for Antibody Development.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c90001) has announced the addition of Stakeholder Opinions: Biologics in Infectious Diseases Well defined target populations are key to commercial success to their offering. Antibody-based agents represent a novel approach to the treatment and prophylaxis of infectious diseases. In recent years, considerable interest has been expressed in their further development, driven by advances in technology that improve manufacturing cost and tolerability: fully human antibody reagents avoid the toxicities associated with traditional human- or animal-derived serum therapy serum therapy n. See serotherapy. . Scope - An overview of the past, current and emerging technologies for biologics as well as obstacles faced in development. - Discussion of antibody products in development for several viral infections and their probable use. - An assessment of pipeline antibody agents targeting important bacterial and fungal nosocomial nosocomial /noso·co·mi·al/ (nos?o-ko´me-il) pertaining to or originating in a hospital. nos·o·co·mi·al adj. 1. Of or relating to a hospital. 2. pathogens. - A review of the key unmet needs within bacterial, viral and fungal infections along with an outline of the commercial outlook for antibody agents. Highlights of this title Antibodies offer several advantages over conventional anti-infectives and vaccines but their cost and mode of administration limits their use in certain areas. A high unmet need and defined target groups are required to gain commercial success. Pipeline products fulfilling these criteria have a greater chance of commercial and scientific success. Accounting for the majority of nosocomial infections, MRSA MRSA Methicillin-resistant Staphylococcus aureus. See MARSA. is the most popular target for antibody development. Despite concerns over resistance there are still several antibiotics that can treat multi-drug resistant S.aureus The aureus (pl. aurei) was a gold coin of ancient Rome valued at 25 silver denarii. The aureus was regularly issued from the 1st century BC to the beginning of the 4th century AD, when it was replaced by the solidus. , reducing the need for antibody-based therapeutics. The greater need lies in treatment of Pseudomonas Pseudomonas A genus of gram-negative, nonsporeforming, rod-shaped bacteria. Motile species possess polar flagella. They are strictly aerobic, but some members do respire anaerobically in the presence of nitrate. and fungal infections. For most viral infections, conventional therapies are able to control disease progression effectively. In HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. and HCV HCV abbr. hepatitis C virus HCV 1 Hepatitis C virus, see there 2. Human coronavirus. See Coronavirus. the real need is for a cure or preventative measure but the majority of pipeline products are being developed for treatment of these infections. Key reasons to purchase this title - Identify the key antibody products in development for bacterial, viral and fungal infections. - Examine the remaining and emerging unmet needs in the infectious diseases market and identify opportunities for antibody product development. - Gain an overview of the commercial outlook for antibody based products and their likely positioning in the prophylaxis and treatment of infections. Content Outline: Chapter 1 Executive Summary Chapter 2 Commercial Outlook Chapter 3 Biologics Technology Overview Chapter 4 Antivirals Chapter 5 Antibacterials Chapter 6 Antifungals Bibliography Appendix B List of Tables List of Figures Companies Mentioned: - Amgen Inc. - Arab Banking Corporation - AVANIR Pharmaceuticals - CDC See Control Data, century date change and Back Orifice. CDC - Control Data Corporation SPA - Dyax Corp - GlaxoSmithKline Plc - Hammond Logistics Group Ltd. - Hewlett-Packard Company - Human Genome Sciences Human Genome Sciences NASDAQ: HGSI is a biopharmaceutical corporation founded in 1992. Its stated purpose is to "discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs. Inc. - ICU ICU intensive care unit. ICU abbr. intensive care unit ICU see intensive care unit. ICU Medical Inc - Inhibitex, Inc. - Insight Communications Company, Inc For more information visit http://www.researchandmarkets.com/reports/c90001. Source: Datamonitor |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion